ArticleRespiratory research2025
Article in Respiratory research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- METLUNG: plasma metabolomic profiling identifies metabolomic signatures associated with immunotherapy outcomes in non-small cell lung cancer.Journal for immunotherapy of cancer · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundWhether metabolic parameters on PET/CT are noninvasive alternatives to programmed cell death ligand 1 (PD-L1) expression and tumor mutational burden (TMB) in adenocarcinoma (ADC) and squamous cell carcinoma (SCC) remains unknown. We identified predictors and developed PET/CT-based nomogram models for predicting PD-L1 expression and TMB, and tested the usefulness of models for stratifying immunotherapy responses.
methodsWe enrolled 305 patients with non-small cell lung cancer from January 2017 to April 2024 as the primary cohort to investigate independent predictors of PD-L1 expression and TMB for ADC (n = 183) and SCC (n = 122). Clinicopathological characteristics, semantic CT features, and PET metabolic parameters were reviewed and analyzed. Significant predictors of ADC biomarkers were identified, and ADC were randomly assigned 7:3 to the training (n = 128) and validation (n = 55) cohorts to develop and validate predictive models for PD-L1 expression, TMB, and the combination of both. Clinical, SUL
resultsPD-L1 expression did not differ significantly between SCC and ADC; however, the TMB was significantly higher in SCC (10 vs. 5 mutations/Mb, p < 0.001). In the analysis of ADC, PD-L1 expression was associated with clinical stage, differentiation, and EGFR mutation status (p < 0.05). TMB was associated with age, gender, smoking history, and EGFR mutation status (p < 0.05). SUL
conclusionSUL
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.